Semaglutide 3mg (GLP-1 Analogue)

£110.00

Semaglutide is a derivative of the naturally occurring GLP-1, a peptide known to lower blood sugar levels and enhance insulin secretion. Research shows that Semaglutide may also improve heart, liver, and lung function while helping to slow or prevent the effects of Alzheimer’s disease. Semaglutide has been shown to significantly decrease appetite by delaying gastric emptying and reducing intestinal motility. Glucagon-Like Peptide-1 (GLP-1) Analog Shown to Stimulate Insulin and Suppress Glucagon Secretion in a Glucose-Dependent Manner.

Description

Semaglutide 3mg (GLP-1 Analogue)

Semaglutide 3mg is the first of a new generation of highly effective hormone-based obesity medications. Semaglutide 3mg mimics a hormone called glucagon-like peptide-1 (GLP-1), which is secreted in the gut and targets receptors throughout the body, including the brain. When a person is eating, GLP-1 sends the brain the “I’m full” signal. The main way semaglutide helps treat obesity is through its action in the brain. For many people, the medication appears to work.

The results of a clinical trial, published in The New England Journal of Medicine, showed in addition to the 12.5% mean weight reduction above the placebo group (which included lifestyle changes only) -more than a third of the participants (some of whom weighed more than 200 pounds) lost 20% of their weight.

Semaglutide acts like human glucagon-like peptide-1 (GLP-1) in that it increases insulin secretion, thereby increasing sugar metabolism. It is distributed as a metered subcutaneous injection in a prefilled pen, or as an oral form. One of its advantages over other antidiabetic drugs is that it has a long duration of action, so a once-a-week injection is sufficient. Semaglutide is indicated as an adjunct to diet and exercise to improve glycemic control in adults.